| Dr Shahin Hajbarat, PT, DPT | |
|
10801 Lockwood Dr Ste 180, Silver Spring, MD 20901-1559 | |
| (240) 480-4553 | |
| (301) 972-1068 |
| Full Name | Dr Shahin Hajbarat |
|---|---|
| Gender | Male |
| Speciality | Physical Therapy |
| Experience | 3 Years |
| Location | 10801 Lockwood Dr Ste 180, Silver Spring, Maryland |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1124784236 | NPI | - | NPPES |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Rehabneeds | 6507017712 | 7 |
News Archive
Patients with combined pulmonary fibrosis and emphysema who are undergoing treatment for advanced lung cancer do not have a significantly worse prognosis than their counterparts with isolated idiopathic interstitial pneumonias, report Japanese researchers.
CytomX Therapeutics, a biotechnology company focused on the development of proteolytically-activated antibodies, today announced it has completed a $30 million Series B financing.
The Partnership for Safe Medicines, a nonprofit coalition of more than 40 healthcare and anti-counterfeiting groups, today expressed support for Mayor Giuliani and the National Association of Boards of Pharmacy (NABP) to educate Americans about the dangers of buying medicines from unknown, foreign sources and to tighten the rules for the distribution and sale of prescription drugs in the United States.
Quest PharmaTech Inc., a pharmaceutical company developing and commercializing products for the treatment of cancer, today announced that it has received notice of allowance for U.S. Patent Application 10/831,886 entitled: "Combination Therapy for Treating Disease".
Nipro Corporation, through its wholly-owned subsidiary Nippon Product Acquisition Corporation (the "Purchaser"), today commenced a cash tender offer to purchase all outstanding shares of Home Diagnostics, Inc. pursuant to an Agreement and Plan of Merger among Nipro, the Purchaser and Home Diagnostics dated February 2, 2010 (the "Merger Agreement").
› Verified 7 days ago
| Entity Name | Rehabneeds |
|---|---|
| Entity Type | Part B Supplier - Physical/occupational Therapy Group In Private Practice |
| Entity Identifiers | NPI Number: 1891046934 PECOS PAC ID: 6507017712 Enrollment ID: O20121116000461 |
News Archive
Patients with combined pulmonary fibrosis and emphysema who are undergoing treatment for advanced lung cancer do not have a significantly worse prognosis than their counterparts with isolated idiopathic interstitial pneumonias, report Japanese researchers.
CytomX Therapeutics, a biotechnology company focused on the development of proteolytically-activated antibodies, today announced it has completed a $30 million Series B financing.
The Partnership for Safe Medicines, a nonprofit coalition of more than 40 healthcare and anti-counterfeiting groups, today expressed support for Mayor Giuliani and the National Association of Boards of Pharmacy (NABP) to educate Americans about the dangers of buying medicines from unknown, foreign sources and to tighten the rules for the distribution and sale of prescription drugs in the United States.
Quest PharmaTech Inc., a pharmaceutical company developing and commercializing products for the treatment of cancer, today announced that it has received notice of allowance for U.S. Patent Application 10/831,886 entitled: "Combination Therapy for Treating Disease".
Nipro Corporation, through its wholly-owned subsidiary Nippon Product Acquisition Corporation (the "Purchaser"), today commenced a cash tender offer to purchase all outstanding shares of Home Diagnostics, Inc. pursuant to an Agreement and Plan of Merger among Nipro, the Purchaser and Home Diagnostics dated February 2, 2010 (the "Merger Agreement").
› Verified 7 days ago
| Entity Name | Maryland Luna Care Physical Therapy Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1083340988 PECOS PAC ID: 4284017419 Enrollment ID: O20220819002194 |
News Archive
Patients with combined pulmonary fibrosis and emphysema who are undergoing treatment for advanced lung cancer do not have a significantly worse prognosis than their counterparts with isolated idiopathic interstitial pneumonias, report Japanese researchers.
CytomX Therapeutics, a biotechnology company focused on the development of proteolytically-activated antibodies, today announced it has completed a $30 million Series B financing.
The Partnership for Safe Medicines, a nonprofit coalition of more than 40 healthcare and anti-counterfeiting groups, today expressed support for Mayor Giuliani and the National Association of Boards of Pharmacy (NABP) to educate Americans about the dangers of buying medicines from unknown, foreign sources and to tighten the rules for the distribution and sale of prescription drugs in the United States.
Quest PharmaTech Inc., a pharmaceutical company developing and commercializing products for the treatment of cancer, today announced that it has received notice of allowance for U.S. Patent Application 10/831,886 entitled: "Combination Therapy for Treating Disease".
Nipro Corporation, through its wholly-owned subsidiary Nippon Product Acquisition Corporation (the "Purchaser"), today commenced a cash tender offer to purchase all outstanding shares of Home Diagnostics, Inc. pursuant to an Agreement and Plan of Merger among Nipro, the Purchaser and Home Diagnostics dated February 2, 2010 (the "Merger Agreement").
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Shahin Hajbarat, PT, DPT 2401 Research Blvd Ste 101, Rockville, MD 20850-3215 Ph: (240) 480-4553 | Dr Shahin Hajbarat, PT, DPT 10801 Lockwood Dr Ste 180, Silver Spring, MD 20901-1559 Ph: (240) 480-4553 |
News Archive
Patients with combined pulmonary fibrosis and emphysema who are undergoing treatment for advanced lung cancer do not have a significantly worse prognosis than their counterparts with isolated idiopathic interstitial pneumonias, report Japanese researchers.
CytomX Therapeutics, a biotechnology company focused on the development of proteolytically-activated antibodies, today announced it has completed a $30 million Series B financing.
The Partnership for Safe Medicines, a nonprofit coalition of more than 40 healthcare and anti-counterfeiting groups, today expressed support for Mayor Giuliani and the National Association of Boards of Pharmacy (NABP) to educate Americans about the dangers of buying medicines from unknown, foreign sources and to tighten the rules for the distribution and sale of prescription drugs in the United States.
Quest PharmaTech Inc., a pharmaceutical company developing and commercializing products for the treatment of cancer, today announced that it has received notice of allowance for U.S. Patent Application 10/831,886 entitled: "Combination Therapy for Treating Disease".
Nipro Corporation, through its wholly-owned subsidiary Nippon Product Acquisition Corporation (the "Purchaser"), today commenced a cash tender offer to purchase all outstanding shares of Home Diagnostics, Inc. pursuant to an Agreement and Plan of Merger among Nipro, the Purchaser and Home Diagnostics dated February 2, 2010 (the "Merger Agreement").
› Verified 7 days ago